



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > Olmesartan + hydrochlorothiazide > Printer-friendly PDF

Olmesartan + hydrochlorothiazide

Trade Name:

Olmetec Plus

Manufacturer/Distributor:

Schering-Plough

www.schering-plough.ca, 1-800-463-5442 (Medical Information)

Classification:

Antihypertensive agent

ATC Class:

C09DA08 Olmesartan medoxomil and diuretics

Status:

active

Notice of Compliance (yyyy/mm/dd):

2008/11/21

Date Marketed in Canada (yyyy/mm/dd):

2009/02

Presentation:

tablet: 20 mg olmesartan + 12.5 mg hydrochlorothiazide, DIN: 02319616

tablet: 40 mg olmesartan + 12.5 mg hydrochlorothiazide, DIN: 02319624

tablet: 40 mg olmesartan + 25 mg hydrochlorothiazide, DIN:02319632

Comments:

Not for initial therapy. For treatment of mild to moderate hypertension in patients who are not adequately controlled on either olmesartan or hydrochlorothiazide alone.

Keywords: olmesartan

hydrochlorothiazide

angiotensin receptor blockers

diuretics

hypertension

Access:

public

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the xʷməkʷəy̓əm (Musqueam), Skwxwú7mesh Uxwumixw (Squamish Nation), and səl̓ilw̓ətaʔ (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-09-05 19:47): <http://www.dpic.org/druglisting/olmesartan-hydrochlorothiazide>